10 completed, 5 active not recruiting, 5 recruiting. 13 Phase 2, 7 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 5, Active not recruiting 4, Completed 4 |
| Phase 1 | 7 | Completed 5, Active not recruiting 2 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow Grade 1 Follicular Lymphoma: new trials by email Literature Review of Grade 1 Follicular Lymphoma trials Research Report on Grade 1 Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial Pirtobrutinib, Mosunetuzumab, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 22 | 2025-11-17 | 2026-06-04 |
| Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Recruiting | University of Washington | 20 | 2024-08-29 | 2026-08-27 |
| Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma Zanubrutinib, Rituximab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2024-07-10 | 2026-07-20 |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin - Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Completed | University of Washington | 42 | 2022-03-23 | 2026-05-13 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | Emory University | 49 | 2021-09-03 | 2026-02-09 |
| Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma Ibrutinib, Obinutuzumab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma | Phase 2 | Active not recruiting | University of California, Davis | 40 | 2021-02-24 | 2026-04-13 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas Anti-OX40 Antibody BMS 986178, Laboratory Biomarker Analysis, Radiation Therapy - B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Ronald Levy | 14 | 2018-04-09 | 2024-12-11 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2018-02-20 | 2026-08-18 |
| Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 73 | 2018-01-23 | 2026-07-08 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Active not recruiting | Beth Christian | 22 | 2017-02-21 | 2026-09-24 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101 - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 21 | 2016-11-07 | 2024-10-16 |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 48 | 2016-04-11 | 2024-09-24 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma | Not applicable | Completed | Mayo Clinic | 29 | 2016-01-19 | 2019-11-15 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia cefepime hydrochloride - Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 70 | 2011-02-01 | 2018-07-18 |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma dendritic cell vaccine therapy, cryotherapy, pneumococcal polyvalent vaccine - Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Early Phase 1 | Completed | Mayo Clinic | 16 | 2010-11-01 | 2020-01-14 |
| Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Cytology Specimen Collection Procedure - Adult Immunoblastic Lymphoma, Central Nervous System Non-Hodgkin Lymphoma | Completed | Children's Oncology Group | 174 | 2005-05-30 | 2023-10-03 |
Lymphoma, Follicular (20) · Lymphoma, B-Cell, Marginal Zone (11) · Lymphoma, Mantle-Cell (9) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma, Large B-Cell, Diffuse (5) · Burkitt Lymphoma (4) · Lymphoma, B-Cell (4) · Lymphoma, Large-Cell, Immunoblastic (3) · Lymphoma, T-Cell, Cutaneous (2) · Lymphoproliferative Disorders (2) · Mycosis Fungoides (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Sezary Syndrome (2) · Anemia (1)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Lymphoma (19) · Lymphoproliferative Disorders (18) · Lymphoma, Non-Hodgkin (14) · Lymphoma, B-Cell (8) · Hematologic Diseases (7) · Chronic Disease (6) · Disease Attributes (6) · Leukemia (6) · Leukemia, B-Cell (6)
obinutuzumab (7) · Magnetic Resonance Spectroscopy (5) · ibrutinib (5) · Biopsy (3) · Lenalidomide (3) · Rituximab (3) · Specimen Handling (3) · venetoclax (3) · CT-P10 (2) · Radiation (2) · Radiotherapy (2) · acalabrutinib (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Bendamustine Hydrochloride (1)
University of Washington (5) · Mayo Clinic (2) · Alexey Danilov, MD (1) · Beth Christian (1) · Children's Oncology Group (1) · Chinese PLA General Hospital (1) · Emory University (1) · Kami Maddocks (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Robert Lowsky (1) · Ronald Levy (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of California, Davis (1) · Wake Forest University Health Sciences (1)
United States (19) · Australia (1) · Canada (1) · China (1) · Puerto Rico (1)
Ajay Gopal (2) · Mengyang Di, MD, PhD (2) · Ronald Levy (2) · Amanda M Termuhlen (1) · Beth Christian, MD (1) · Craig Okada, M.D. (1) · John Williamson (1) · Jonathon B Cohen, MD, MS (1) · Joseph M Tuscano (1) · Kami Maddocks, MD (1) · Loretta J Nastoupil (1) · Michael Khodadoust (1) · Paul M Barr (1) · Ryan Lynch, MD (1) · Thomas Witzig (1)
PMID 34780125, PMID 34196037, PMID 35135810, PMID 37939259, PMID 37985359, PMID 42600120
R35CA197353 (2), P30CA015083 (1), P30CA016058 (1), P30CA093373 (1), P30CA138292 (1), U10CA098543 (1), U10CA180888 (1), UG1CA189958 (1)